Magtech: Costs and benefits of magtrace® in breast surgery.
Magtech: Cost effectiveness and benefits of magtrace® versus Technetium in sentinel node biopsy for breast cancer.
- Hospital – Speciality: Wythenshawe Hospital – Breast Cancer
- Study type: Interventional
- Funder: Endomagnetics
Summary
Women with a small breast cancer require surgery to remove the cancer from their breast and also to remove a few lymph nodes from their armpit (sentinel node biopsy) at the same time to see whether the cancer has spread. These
women have an injection of a dye before their surgery which demonstrates the lymph nodes the surgeon needs to remove. This study aims to compare the cost-effectiveness of two commonly used types of dye for sentinel node biopsy – Magtrace and technetium. 50 patients will be randomized to have either Magtrace or Technetium. A research assistant will shadow these women in their visits to the hospital prior to surgery and work out the hospital costs
associated with each treatment. The second phase of the study is a questionnaire of patients and healthcare professionals, asking them what their preferences are in how this type of care is best delivered.
Participant group
Breast cancer patients.
Participant approach
Patients who attend the Manchester University NHS Foundation Trust Breast Service will be approached about participating in the study, before or after their clinic appointment.
Study open date and expected length
Opened: 30 May 2023
Expected end date: 31 July 2024
Results
Pending – this study is still active.
Contact details
Telephone number:0161 291 4494
Email address: breastresearch@mft.nhs.uk
- IRAS number: 293053
